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Abstract
Background: Postnatal glucocorticoid therapy in premature infants diminishes chronic lung disease, but it also increases the
risk of hypertension in adulthood. Since glucocorticoid excess leads to overproduction of free radicals and endothelial
dysfunction, this study tested the hypothesis that adverse effects on cardiovascular function of postnatal glucocorticoids are
secondary to oxidative stress. Therefore, combined postnatal treatment of glucocorticoids with antioxidants may diminish
unwanted effects.
Methodology/Principal Findings: Male rat pups received a course of dexamethasone (Dex), or Dex with vitamins C and E
(DexCE), on postnatal days 1–6 (P1–6). Controls received vehicle (Ctrl) or vehicle with vitamins (CtrlCE). At P21, femoral
vascular reactivity was determined via wire myography. Dex, but not DexCE or CtrlCE, increased mortality relative to Ctrl
(81.3 versus 96.9 versus 90.6 versus 100% survival, respectively; P,0.05). Constrictor responses to phenylephrine (PE) and
thromboxane were enhanced in Dex relative to Ctrl (84.764.8 versus 67.565.7 and 132.764.9 versus 107.064.9% Kmax,
respectively; P,0.05); effects that were diminished in DexCE (58.367.5 and 121.164.3% Kmax, respectively; P,0.05).
Endothelium-dependent dilatation was depressed in Dex relative to Ctrl (115.3611.9 versus 216.9618.9, AUC; P,0.05);
however, this effect was not restored in DexCE (68.368.3, AUC). Relative to Ctrl, CtrlCE alone diminished PE-induced
constriction (43.463.7% Kmax) and the endothelium-dependent dilatation (74.768.7 AUC; P,0.05).
Conclusions/Significance: Treatment of newborn rats with dexamethasone has detrimental effects on survival and
peripheral vasoconstrictor function. Coadministration of dexamethasone with antioxidant vitamins improves survival and
partially restores vascular dysfunction. Antioxidant vitamins alone affect peripheral vascular function.
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Introduction
Glucocorticoids, such as dexamethasone, have been used to
prevent or reduce the incidence of chronic lung disease [1,2], an
important cause of morbidity and mortality in premature infants
[3,4]. Their effectiveness is based on decreasing inflammatory
responses, and accelerating lung maturation and surfactant
production, thereby improving respiratory function in the infant.
Hence, this clinical therapy has greatly decreased neonatal
mortality and facilitated weaning from mechanical ventilation
[2,5].
Despite the well-established beneficial effects of postnatal
glucocorticoid therapy, there has been serious concern regarding
their clinical use because of unwanted side-effects. For instance,
accumulating evidence shows that postnatal treatment with
dexamethasone reduces somatic growth and weight gain in human
infants [6,7] and newborn rats [8,9]. Postnatal dexamethasone
treatment also induces hypertension and cardiomyopathy in
premature babies [1,2,10] and in rat neonates [9,11,12,13]. The
mechanism underlying dexamethasone-induced hypertension may
include glucocorticoid-induced increases in the sensitivity of the
sympathetic nervous system [14], augmentation of vascular
responses to other constrictor neurotransmitters and hormones
[15,16], and a diminished endothelium-dependent vasodilatation
mediated through nitric oxide (NO), prostacyclin (PGI2) or the
endothelium-derived hyperpolarizing factor (EDHF) [17,18].
A separate line of evidence suggests that excess glucocorticoids
promote oxidative stress, both by enhancing the production of
reactive oxygen species (ROS) and/or by reducing the levels of
endogenous antioxidants [19,20]. As oxidative stress plays a major
role in cardiovascular pathology, there is strong evidence that
excessive ROS generation may underlie cardiovascular dysfunc-
tion related to glucocorticoids [19,20].
In this study, we have tested the hypothesis that the unwanted
side-effects of postnatal glucocorticoids on the developing
cardiovascular system are also in part due to glucocorticoid-
induced oxidative stress. If true, combined treatment of premature
infants with glucocorticoid and antioxidants may ameliorate the
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unwanted side-effects while maintaining the beneficial effects of
glucocorticoid therapy in the postnatal period. The hypothesis was
tested by investigating in rats the effects on peripheral vascular
reactivity at weaning of postnatal dexamethasone therapy with or
without vitamins C and E.
Results
Body Weight and Survival
Pups were all born spontaneously on day 22 of gestation with no
difference in birth weight (Table 1). Relative to controls, treatment
with dexamethasone markedly reduced survival. In marked
contrast, co-administration of vitamins C and E with dexameth-
asone significantly improved pup survival (Table 1). The increased
mortality in dexamethasone treated pups was related with a higher
prevalence of observed peritonitis (defined as distended and red
abdomen with diffuse abdominal rigidity) and diarrhoea (yellow
secretions in perianal area), although these comparisons fell
outside statistical significance (Table 1).
At weaning, pups treated with dexamethasone with or without
vitamins C and E were significantly lighter than control pups. By
contrast, pups treated with vitamin C and E alone were
significantly heavier than control pups (Table 1). Similarly, pups
treated with dexamethasone with or without vitamins C and E
opened their eyelids for the first time significantly earlier than
control pups. By contrast, pups treated with vitamin C and E alone
opened their eyelids for the first time significantly later than
control pups (Table 1).
Femoral Vasoconstrictor Function
In pups treated with dexamethasone the maximal contraction
(Emax) to K+ was significantly reduced relative to controls. In
contrast, in pups treated with combined dexamethasone and
vitamins C and E, the maximal constrictor response to K+ was
restored towards control levels. Treatment of pups with vitamins C
and E alone did not have an effect on the contractile response to
K+. There were no differences in the vascular sensitivity to K+
across all four groups (Figure 1A).
Relative to controls, treatment of pups with dexamethasone
increased the maximal contractile response (%Kmax) and the
vascular sensitivity (pD2) to phenylephrine. Treatment of pups
with combined dexamethasone and vitamins C and E restored
towards control levels both the maximal constrictor response and
the sensitivity to phenylephrine. Treatment of pups with vitamins
C and E significantly reduced the maximal response but it did not
affect the sensitivity to phenylephrine (Figure 1B).
Relative to controls, treatment of pups with dexamethasone
increased the maximal contractile response (%Kmax) but not the
vascular sensitivity (pD2) to the thromboxane mimetic agent.
Treatment of pups with combined dexamethasone and vitamins C
and E restored towards control levels the maximal constrictor
response to the thromboxane mimetic agent. In addition, pups
treated with combined dexamethasone and vitamins C and E had
a significantly lower vascular sensitivity to the thromboxane
mimetic agent than pups treated with dexamethasone. There was
no effect on vascular reactivity to the thromboxane mimetic agent
in pups treated with vitamins C and E alone (Figure 1C).
Femoral Vasodilator Function
Endothelium-independent relaxation was assessed by generat-
ing cumulative concentration-response curves to the NO-donor
sodium nitroprusside (SNP) following stable pre-contraction with
1025 mol/L PE. Across all four groups, vessels showed complete
relaxation to SNP, with no differences in Rmax. However, pups
treated with combined dexamethasone and vitamins C and E had
a lower sensitivity to SNP than pups treated with dexamethasone
alone. Pups treated with vitamins C and E alone had a lower
sensitivity to SNP than control pups (Figure 2A).
Endothelium-dependent relaxation was assessed by generating
cumulative concentration response curves to methacholine
(MetCh) after stable pre-contraction with 1025 mol/L PE.
Relative to controls, treatment of pups with dexamethasone or
with vitamins, either in combination or alone, all significantly
reduced the vascular sensitivity to MetCh. However, only pups
treated with combined dexamethasone and vitamins C and E had
a lower maximal relaxant response to MetCh relative to all groups
(Figure 2B).
Further analysis revealed that treatment of pups with dexa-
methasone or with vitamins, either in combination or alone, all
significantly reduced the partial contributions of both NO-
dependent and NO-independent mechanisms mediating the
vascular relaxation (Figure 3). To dissect any effects of treatment
on NO-independent mechanisms contributing to the vasomotor
response induced by MetCh, the contribution of EDHF was
determined. These data show that relative to controls the
contribution of EDHF to the relaxant response induced by MetCh
was maintained in pups treated with dexamethasone but it was
significantly reduced in pups treated with vitamins C and E with or
without dexamethasone (Figure 4).
Discussion
Previous investigation of the effects of glucocorticoids on
vascular function in the perinatal period have been restricted to
the effects in the fetus [21,22,23], the newborn [24,25] or in the
adult offspring [26,27] of antenatal treatment. This is the first
study to determine the effects on vascular function of postnatal
glucocorticoid therapy. The data show that: 1) clinically-relevant
postnatal glucocorticoid therapy increases neonatal mortality, and
augments vasoconstrictor while diminishing vasodilator reactivity
in peripheral vessels isolated from weanling rats; 2) combined
postnatal treatment of glucocorticoids with antioxidants improves
Table 1. Body weight and survival.
Ctrl Dex DexCE CtrlCE
Birth weight (g) 6.460.1 6.760.2 6.460.1 6.960.1
Survival (%) 100 81.3* 96.9 90.6
Peritonitis
(ratio and %)
0/32 (0%) 11/32 (34.4%) 7/32 (21.9%) 1/32 (3.1%)
Diarrhea
(ratio and %)
0/32 (0%) 13/32 (40.6%) 8/32 (25.0%) 0/32 (0%)
P21 Body weight (g) 55.4260.67 49.7160.74* 45.7061.5* 60.5060.67*
Eyes opening (d) 14.160.1 12.660.2* 12.260.3* 14.860.1*
Values are mean 6 S.E.M for body weight at birth and postnatal day 21 (P21),
the percentage of pups surviving, the prevalence of peritonitis or diarrhoea in
pups following treatment, and the postnatal age at which the eyelids first
opened. Groups are control (Ctrl), pups treated with dexamethasone (Dex),
pups treated with dexamethasone combined with vitamins C and E (DexCE)
and pups treated with vitamins C and E alone (CtrlCE). For data on birth weight,
survival, peritonitis and diarrhea n = 32 for all groups; for data on P21 body
weight: Ctrl, n = 32; Dex, n = 26; DexCE, n = 31; CtrlCE, n = 29; and for data on
eyelids opening: Ctrl, n = 32; Dex, n = 26; DexCE, n = 31; CtrlCE, n = 30. Significant
differences (P,0.05) are: *, vs Ctrl (Fisher’s Exact Test for survival, One-Way
ANOVA + Student Newman-Keuls test elsewhere).
doi:10.1371/journal.pone.0009250.t001
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Figure 1. Vasoconstrictor function in pups at P21. Values are the mean 6 S.E.M for the concentration-response curves, the maximal response
(Emax or %Kmax) and the sensitivity (EC50 or pD2) to potassium (K
+, A), phenylephrine (PE, B) and a thromboxane mimetic agent (U46619, C). Groups
are control (Ctrl, open circle/histogram, n = 8), pups treated with dexamethasone (Dex, closed square/histogram, n = 8), pups treated with
dexamethasone combined with vitamins C and E (DexCE, grey square/histogram, n = 8) and pups treated with vitamins C and E alone (CtrlCE, grey
circle and hatched histogram, n= 8). Emax is the maximal effective tension induced by potassium-depolarization and % Kmax is expressed as the
percentage of the maximal vasoconstriction induced by 76.88mM potassium. EC50 is the half maximal effective concentration and pD2 is –log(EC50).
Significant differences (P,0.05) are: * vs Ctrl, { vs Dex (One-Way ANOVA + Student Newman-Keuls Test).
doi:10.1371/journal.pone.0009250.g001
Steroids and Antioxidants
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neonatal survival and partially restores impairments in vascular
reactivity; and 3) postnatal treatment with vitamins alone does not
induce neonatal mortality or affect peripheral constrictor reactivity,
but it diminishes peripheral vasodilator reactivity in weanling rats.
In addition to exogenous vasoactive influences such as
neurotransmitters and hormones, and local factors such as those
produced within the endothelium, it has become increasingly
evident that the cellular oxidant milieu is also an important
modulator of vascular resistance [28]. Vascular endothelial cells
generate reactive oxygen species (ROS), such as the superoxide
anion (NO2
2) [29]. Superoxide readily combines with NO, limiting
its bioavailability [30]. Hence, under physiological conditions,
manipulation of the vascular NO:NO2
2 ratio is also an important
determinant of tone. Data in the present study show that postnatal
dexamethasone treatment diminished the contractile response to
potassium, it increased the contractile responsiveness to a-
adrenergic and local vasoconstrictors, and it depressed endothe-
lium-dependent vasorelaxation. Postnatal treatment with com-
bined dexamethasone and antioxidant vitamins restored contrac-
tile function, and postnatal treatment with vitamins alone
diminished phenylephrine-induced contraction. The latter finding
supports the concept that increased NO bioavailability acts to
oppose tonic vasoconstrictor influences.
The depressive effects of dexamethasone on eNOS expression
in a number of tissues are well described [31,32]. In addition,
dexamethasone may enhance ROS generation directly [19] or
secondary to eNOS uncoupling by limiting the availability of
cofactors such as tetrahydrobiopterin, BH4 [33]. Therefore, the
increased vasoconstrictor responses in dexamethasone-treated
pups in the present study may be due to glucocorticoid-induced
blunting of tonic NO-dependent vasodilatation [15,20]. Alterna-
tively, the sensitizing effects of dexamethasone on vascular
contractile function may be direct due to up-regulation of a-
adrenoceptors in vascular smooth muscle cells (VSMCs), and/or
increased intracellular uptake of calcium ions. For instance,
perinatal dexamethasone is known to alter the pattern and
expression of adrenoceptors in the rat [34] and sheep [35] and
treatment of cultured VSMCs with dexamethasone for 48h
increased expression of a1B adrenoceptor mRNA [36]. Hayashi
et al. [37] observed increased Ca2+ uptake and [3H]-dihydropyr-
idine binding in VSMCs after a 48h dexamethasone incubation,
suggesting that glucocorticoids may enhance VSMC contraction
by inducing synthesis of new Ca2+ channels. The reversal of the
sensitizing effects of dexamethasone on phenylephrine- and
thromboxane-induced contractile function in pups treated with
combined dexamethasone and antioxidants may be due to the
Figure 2. Vasodilator function in pups at P21. Values are the mean 6 S.E.M for the concentration-response curves, the maximal relaxation
(%Rmax) and the sensitivity (pD2) to sodium nitroprusside (SNP, A), and to methacholine (MetCh, B). Group numbers and group symbols are the same
as in Figure 1. Significant differences (P,0.05) are: * vs Ctrl, { vs Dex, { vs all (One-Way ANOVA + Student Newman-Keuls Test).
doi:10.1371/journal.pone.0009250.g002
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effects of antioxidants restoring tonic NO bioavailaibility,
replacing that which was diminished by dexamethasone. Alterna-
tively, the reversal may be due to the effects of antioxidants
increasing NO bioavailaibility, which act to oppose glucocorticoid-
enhanced constrictor mechanisms.
The reduction in maximal tension induced by potassium in
femoral vessels isolated from weanling rats treated with dexa-
methasone may indicate either a reduction in smooth muscle mass,
or an impaired smooth muscle contraction, or both. Since
glucocorticoids are known to inhibit the growth of vascular
smooth muscle cells in culture [38] and to prevent neointimal
vascular hyperplasia after injury in rats [39], it is plausible that a
decrease in the smooth muscle:extracellular matrix ratio may have
produced the decreased responsiveness to potassium. Co-admin-
istration of dexamethasone with vitamins in the present study
promoted recovery of the femoral contractile response to
potassium. Given the lack of an effect of vitamins alone on
potassium-induced contraction, it is unlikely that vitamins improve
this response in dexamethasone-treated rats downstream of the
increase in [Ca2+]i, such as by increasing myosin light chain kinase
activity and/or the rate of cross-bridge cycling. Rather, the
beneficial effects of antioxidant vitamins on potassium-induced
contraction may again be due to correction of the oxidative
imbalance within the vasculature of dexamethasone treated pups.
In the present study, pups treated with dexamethasone showed
depressed vasodilator responses to metacholine, but not to SNP,
indicating impairment of endogenous endothelium-derived vaso-
dilators such as NO, EDHF and PGI2. The partial contributions of
endogenous NO and EDHF to metacholine-induced vascular
relaxation were further investigated following incubation of vessels
with the NO synthase inhibitor L-NAME alone or after both
L-NAME and the cyclooxygenase inhibitor indomethacin. These
studies revealed that the dilator defect induced by dexamethasone
was due to glucocorticoid-induced depression of both NO-
dependent and NO-independent mechanisms. However, within
NO-independent mechanisms, dexamethasone did not affect the
contribution of EDHF, suggesting glucocorticoid-induced depres-
sion of prostanoid-dependent vasodilatation. Accordingly, it has
been previously shown that both glucocorticoids and oxidative
stress inhibit prostacyclin production [17,30].
Postnatal treatment of pups with antioxidant vitamins alone or
in combination with dexamethasone decreased NO-dependent
vasodilator mechanisms, it almost abolished the contribution of
EDHF to vasorelaxation, and it decreased femoral dilator
reactivity to SNP. These effects may be due to negative feedback
as a result of antioxidant vitamin-induced increases in NO
bioavailability, which in turn may down-regulate the VSMC
dilator pathway. For instance, chronic increases in NO have been
reported to down-regulate sGC expression [40,41] and to increase
PDE function [42], thereby reducing SMC dilator capacity.
Furthermore, inhibition of the NO-cGMP-PKG pathway will
diminish VSMC relaxation due to lack of activation of calcium
activated potassium channels [43,44].
A final component of the data in the present study show that
postnatal dexamethasone treatment increased neonatal mortality and
accelerated maturational processes indexed by early eyelid opening,
confirming previous obvervations in rat studies [9,45,46]. Interest-
ingly, postnatal treatment with dexamethasone in combination
with antioxidant vitamins did not prevent the maturational effects
of glucocorticoids, but it markedly improved neonatal survival.
Taken together, the data suggest that combined glucocorticoid and
Figure 3. Partial contribution of NO-dependent and NO-
independent mechanisms to the endothelial-dependent relax-
ation. Values are the mean 6 S.E.M for the area under the curve (AUC)
for MetCh-induced relaxation (complete bar with positive S.E.M.), the
AUC for MetCh-induced relaxation following treatment with LNAME
(NO-independent component, white bar with negative S.E.M.), and the
remaining AUC after MetCh with LNAME (NO-dependent component,
black bar with negative S.E.M). Group numbers are the same as in
Figure 1. Significant differences P,0.05: * vs Ctrl for complete bar; { vs
Ctrl for white bar, { vs Ctrl for black bar (One-Way ANOVA + Student
Newman-Keuls Test).
doi:10.1371/journal.pone.0009250.g003
Figure 4. Partial contribution of EDHF to the NO-independent
relaxation. Values are the mean 6 S.E.M for the area under the curve
(AUC) representing the relaxation mediated by the endothelium-
derived hyperpolarizing factor (EDHF). The relaxant contribution
mediated by EDHF is calculated by the AUC of MetCh-induced
relaxation in the presence of LNAME and indomethacin. Groups are
control (Ctrl, open histogram, n = 6), pups treated with dexamethasone
(Dex, closed histogram, n= 6), pups treated with dexamethasone
combined with vitamins C and E (DexCE, grey histogram, n = 6) and
pups treated with vitamins C and E alone (CtrlCE, hatched histogram,
n = 6). Significant differences (P,0.05) are: * vs Ctrl or Dex (One-Way
ANOVA + Student Newman-Keuls Test).
doi:10.1371/journal.pone.0009250.g004
Steroids and Antioxidants
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antioxidant treatment may diminish some of the adverse conse-
quences of postnatal glucocorticoid therapy on mortality and on
vascular function while maintaining maturational effects.
In conclusion, treatment of newborn rats with dexamethasone
has detrimental effects on survival and peripheral vasoconstrictor
function. Co-administration of dexamethasone with antioxidant
vitamins improves survival and partially restores vascular dysfunc-
tion. Administration of vitamins alone to healthy pups decreases
vasodilator capacity. The data support the hypothesis tested that
unwanted side-effects of postnatal glucocorticoids on the develop-
ing cardiovascular system are in part due to glucocorticoid-
induced oxidative stress, and that combined treatment of
premature infants with glucocorticoid and antioxidants may
ameliorate the unwanted side-effects while maintaining the
beneficial effects of glucocorticoid therapy in the postnatal period.
Materials and Methods
Animals
All procedures were performed under the UK Animals
(Scientific procedures) Act 1986 and were approved by the Ethical
Review Committee of the University of Cambridge. Pregnant
Wistar rats (n = 32; Charles River, UK) with timed gestations
were individually housed under standard conditions (21uC room
temperature/55% room humidity, light:dark, 12:12 hour) with ad
libitum access to food (Special Diet Services, UK) and water. At
birth (postnatal day 0, P0), each litter was sexed and the pups were
weighed and culled to eight (four males/four females) to
standardize feeding and maternal care within any one litter. All
pups remained with their mothers until weaning at postnatal day
21 (P21).
Postnatal Treatment Regimen
To exclude differences due to sex, only male rat pups were
studied. The 4 male pups from each litter were randomly assigned
to one of four treatments: Ctrl: n = 32; Dex: n = 32; DexCE:
n= 32; CtrlCE: n= 32. Pups received two intraperitoneal (i.p.)
injections per day (10 mL.g21 each) of some or all of the following
solutions (Sigma-Aldrich, UK): dexamethasone (Dexamethasone-
21-phosphate, disodium salt), vitamin C (L-ascorbic acid), and
vitamin E (dl-a-tocopherol acetate). Two injections were used due
to the different solubility of vitamin E (dissolved in groundnut oil)
and vitamin C and dexamethasone (in 0.9% NaCl). Ctrl pups
received injections of the vehicles saline and groundnut oil for the
duration of the treatment period (P1–6). Dex pups received a
three-day, tapering course (0.5, 0.3, and 0.1 mg.g21.day21) plus
separate injections of oil on P1–P3 and then only saline and oil
from P4–P6. DexCE pups received the same treatment as Dex,
plus vitamins C (200 mg.kg21.day21) and E (100 mg.kg21.day21)
from P1–6. The CtrlCE pups received vitamins from P1–6. In our
study, the dose and duration of the treatment was based on and is
proportional to a 21-day tapering course of dexamethasone in
humans. For extrapolation of postnatal treatment with dexameth-
asone in human neonates to postnatal treatment with dexameth-
asone in rat pups, the exposure to glucocorticoids has been
estimated as a percentage of the total lactation period in the
different species [11]. In humans, lactation averages 6 months. A
21-d tapering course of dexamethasone represents ca. 12% of the
lactation period in humans. In rats, lactation is 21 days. 12% of the
lactation period in rats is ca. 3 days. Doses of vitamins C and E
used were adopted from studies indicating successful antioxidant
effects in adult rats [47]. Ascorbic acid and a-tocopherol were
combined as they act synergistically to provide optimal conditions
for NO production [48].
Wire Myography
At P21, to exclude differences due to within-litter variation,
femoral arteries were isolated and collected from one male
randomly chosen pup from each litter (Ctrl: n = 8; Dex: n= 8;
DexCE: n= 8; CtrlCE: n= 8). These pups were humanely killed
by CO2 inhalation and posterior cervical dislocation and their
body weight (BW) was determined. Rats were kept on ice until
vessel dissection. Under a bifocal dissecting microscope (Brunel
Microscopes Ltd.), the first branch from the femoral artery of the
left hind limb was excised via a medial incision. The vessel was
placed in a Petri dish in phosphate-buffered saline kept on ice and
carefully cleaned of adventitial, adipose and connective tissue. An
arterial segment of approximately 2 mm length was cut and
carefully threaded with a stainless steel wire (40 mm diameter). The
threaded vessel segment was then placed between the mounting
support jaws of a four-chamber small-vessel wire myograph (Multi
Wire Myograph System 610M, DMT, Denmark). The wire was
secured with screws to the jaw attached to the force transducer. A
second wire was then passed through the arterial segment and its
extremes fixed to the jaw attached to a micropositioner. The vessel
segment was bathed in Krebs solution (mmol.l21: NaCl 118.5,
Fisher, KCl 4.75, Sigma, MgSO4N7H20 1.2, Sigma, KH2PO4 1.2,
Sigma, NaHCO3 25.0, Sigma, CaCl2 2.5, Sigma, glucose 11.1,
Sigma, UK) and gassed continuously with 5% CO2 and 95% O2
at 37uC in the myograph chamber.
Following a 15 minute equilibration period, the vessel was
stretched in a stepwise manner to a standardized tension equivalent
to a physiological transmural pressure [49]. This was done to
simulate conditions in vivo for two main reasons; first, because the
stimulated vascular response is dependent on the degree of
stretch; and secondly, because this degree of stretch gives the
maximal vascular response [50]. To test maximal contractile
capacity, a potassium (K+) concentration-response curve was
generated following a 20 minute equilibration period by
subjecting vessels to increasing doses of a K+ solution (4.76mM
to 100.94mM), washing with Krebs solution twice between doses.
Cumulative concentration-response curves to the a1-adrenergic
agonist phenylephrine (PE; 10210–1025 mol/L) and the throm-
boxane mimetic U46619 (10213–1027 mol/L) were determined
in half-log increments. The relaxant effects of sodium nitroprus-
side (SNP; 10210–1024 mol/L) and methacholine (MetCh;
10210–1024 mol/L) were determined after pre-contraction with
phenylephrine (1025 mol/L). To determine the partial contribu-
tions of endogenous nitric oxide (NO) and EDHF to MetCh-
induced vascular relaxation, additional concentration-response
curves to MetCh were also determined after incubation with
either L-NAME (1025 mol/L) alone or after both L-NAME and
indomethacin (1026 mol/L). Between experiments, vessels were
washed repeatedly with Krebs solution and allowed to equilibrate
in Krebs solution for at least 20 minutes.
Data and Statistical Analyses
The vascular response to potassium was analyzed using the
Boltzmann sigmoidal analysis, and the maximal effective tension
(Emax) and the half maximal effective concentration (EC50) were
determined. All other concentration-response curves were ana-
lyzed using an agonist-response best-fit line, where the maximal
vasomotor response was expressed as percentage of the contrac-
tion induced by 76.88 mM K+ (%Kmax for constriction, %Rmax
for relaxation) and the vascular sensitivity was expressed as
pD2(2logEC50).
Differences in the vascular responses were compared by
calculating the area under the curve using the following equation:
Steroids and Antioxidants
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Area~1=2 x1zxnð Þz
Xk~n{1
k~2
xk
Where x is the response variable, n is the number of dose intervals
during the protocol and xk is the response in the kth interval.
The contribution of NO to the vascular relaxation induced by
MetCh was calculated by subtracting the area under the curve
(AUC) for MetCh – the AUC for MetCh + LNAME. The
contribution of NO-independent mechanisms to the vascular
relaxation induced by MetCh was calculated by the AUC for
MetCh + LNAME. The EDHF dependent relaxation was
calculated by the AUC after MetCh + LNAME & indomethacin.
Data are presented as mean 6 S.E.M unless otherwise stated.
Ratios and percentages were arcsine transformed prior to statistical
analysis. Survival data were compared statistically using Fisher’s
Exact Test. Other data were compared statistically by One-Way
ANOVA followed by the Student Newman-Keuls post hoc test.
Significance was accepted when P,0.05 (SigmaStat 2.0; SPSS Inc.,
Chicago, USA).
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